NDD Europe 2019

Memo

Multiple clinical failures in the neurodegenerative field have sparked realisation that there is a critical need for discussion and debate between neurodegenerative drug developers to drive clinical success. NDD Europe will overcome the translational challenges facing neurodegenerative drug developers by exploring the future biomarkers of neurodegeneration, improving preclinical modelling to increase clinical predictability and encouraging precompetitive strategies and collaboration amongst drug developers. With 70+ thought-leaders converging at NDD Europe, this will be an unrivalled opportunity for you to gain the latest scientific insights, have your peers review your research and grow your collaborator network. Key talks form industry experts will address: - Seeking blood-based biomarkers to advance patient stratification and diagnosis- Assessing CSF-based and imaging biomarker techniques to improve biomarker translatability- Exploring novel preclinical models for neurodegeneration to allow disease recapitulation- Evaluating different approaches for targeting neurodegeneration and efficiently crossing the blood-brain barrier for drug delivery and target engagement NDD Europe will provide a platform for creative thinking, encouraging debate and communication to enable the neurodegeneration field to shape their future research with reduced risk and greater efficiency. Prices:Gold: Conference + 2 Workshops: EUR 3097.0,Silver: Conference + 1 Workshop: EUR 2698.0,Bronze: Conference Only: EUR 2299.0,Workshop(s) Only: EUR 499.0 Speakers: Angel Cedazo-Minguez, Head of Neuroscience Research, Sanofi, Alastair D. Reith, Senior Director, External Innovation, GSK , Andy Takle, Executive Director and Head, Hatfield Research Laboratories, Neurology Business Group, Eisai, Carol Routledge, Director of Research, Alzheimer's Research UK , Gary Gilmour, Research Advisor, Translational and Integrative Neuroscience, Eli Lilly , Hugh Marston, Senior Research Fellow and Head of Translational Neuroscience, Eli Lilly , Jan Egebjerg Jensen, Senior Director, Neurodegeneration Discovery Biology, Janssen, Jan Torleif Pedersen, Director, Therapeutic Biology Lead, Alzheimer’s Disease and Dementia, Neuroscience, Lundbeck , Luc Ver Donck, Scientific Director, Head of Alzheimer Disease Animal Models, Neuroscience Discovery, Janssen , Mark Schmidt, Senior Director, Janssen , Nathalie Cartier-Lacave, Acting Chief Scientific Officer, BrainVectis, Patrick Downey, Director, Head of Neurodegeneration, UCB, Ralph Laufer, Chief Scientific Officer, Lysogene, Richard Wyse, Global Director of Research and Development, The Cure Parkinson's Trust, Ross Jeggo, Head of Research, Neuropsychiatry Centre for Therapeutic Innovation, Servier, Tania Nikolcheva, Principal Medical Director, Roche, Tauseef Butt, Chief Executive Officer, Progenra, Ulf Andreasson, Associate Professor, University of Gothenburg Time: 10:00 am - 5:00 pm